Browse News
Filter News
Found 180 articles
-
Algernon Pharmaceuticals CEO Christopher J. Moreau to Be Featured on Radius Research's Pitch, Deep Dive and Q&A Webinar on April 16th, 2024
4/11/2024
Algernon Pharmaceuticals Inc., is pleased to invite investors and other interested parties to participate in an upcoming special CEO interview and Q & A session on April 16th, 2024, at 4 PM ET / 1 PM PT, hosted by Market Radius Research.
-
Algernon Pharmaceuticals Announces Closing of the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position
3/27/2024
Algernon Pharmaceuticals Inc. is pleased to announce that it has closed on its agreement with Seyltx Inc., a privately owned U.S. based drug development company, for the acquisition of Algernon’s NP-120 research program for the purchase price of USD $2M cash and a 20% common share equity position in Seyltx.
-
Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat CKD
1/31/2024
Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a Canadian clinical stage pharmaceutical development company, is pleased to announce that it has received a notice of intention to grant from the Chinese Patent Office for patent application No. 201980043698.6 for its antifibrotic drug candidate NP-251 (Repirinast).
-
Algernon Pharmaceuticals Announces Notice of Allowance for Ifenprodil Patent in Japan for Idiopathic Pulmonary Fibrosis
1/11/2024
Algernon Pharmaceuticals Inc. is pleased to announce that it has received a notice of allowance from the Japanese Patent Office for patent application No. 2021-547495 entitled: Compositions and Methods for Treating Idiopathic Pulmonary Fibrosis (IPF).
-
Algernon Pharmaceuticals Announces Increase to Private Placement - December 27, 2023
12/27/2023
Algernon Pharmaceuticals Inc. a Canadian clinical stage pharmaceutical development company announces an increase to its non-brokered private placement, previously announced on December 12, 2023, from gross proceeds of $150,000 to $280,000 of units at an issue price of $0.075 per Unit.
-
Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat NASH and NAFLD
11/30/2023
Algernon Pharmaceuticals Inc. is pleased to announce that it has received a notice of intention to grant from the Chinese Patent Office for patent application No. 112654357 entitled “Compositions and Methods for Treating Non-Alcoholic Steatohepatitis” with NP-251 (Repirinast).
-
Algernon Pharmaceuticals Announces LOI for the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position
11/22/2023
Algernon Pharmaceuticals Inc. is pleased to announce that it has signed a Letter of Intent (“LOI”) with Seyltx Inc. (“Seyltx”), a privately owned U.S. based drug development company, to acquire Algernon’s NP-120 (“Ifenprodil”) research program for USD $2M cash.
-
Algernon Pharmaceuticals Receives Japanese Patent Notice of Allowance for Treatment of NASH with Repirinast
11/8/2023
Algernon Pharmaceuticals Inc. is pleased to announce that it has received a Notice of Allowance from the Japanese Patent Office for patent application No. 2021-512244 entitled “Compositions and Methods for Treating Non-Alcoholic Steatohepatitis” with NP-251 (Repirinast).
-
Clinical Trials Market is Rising Rapidly Up to USD 95 BN by 2030
10/18/2023
As per Vision Research Reports, the global clinical trials market size is expected to surpass around USD 95 billion by 2030 from valued USD 51.78 billion in 2022, expanding growth at a CAGR of 7.07% during forecast period 2022 to 2030.
-
Algernon NeuroScience Announces 40 Patient Phase 2 Psychedelic Drug DMT Stroke Study
8/8/2023
Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that its subsidiary Algernon NeuroScience (AGN Neuro), has completed a feasibility study and has finalized its clinical trial design for a 40 patient Phase 2 DMT Stroke study.
-
Algernon Pharmaceuticals Announces Private Placement and Issuance of Shares in Connection with Financial Advisory Agreement
7/14/2023
Algernon Pharmaceuticals Inc. announces a non-brokered private placement for gross proceeds of CDN$205,000 (the “ Offering ”) of units (the “ Units ”) at an issue price of CDN$0.20 per Unit.
-
Algernon Pharmaceuticals Engages Maxim Group to Explore Spin-Off of its Ifenprodil Phase 2 Chronic Cough Drug Development Program
6/27/2023
Algernon Pharmaceuticals Inc. is pleased to announce that it has engaged Maxim Group LLC (“Maxim”) to provide financial advisory and investment banking services, and to assist in identifying and evaluating potential M&A and strategic opportunities, including the potential spin-off of the Company's NP-120 (“Ifenprodil”) chronic cough research program.
-
Algernon Pharmaceuticals to Present Phase 2 Ifenprodil Cough Data at the 2023 American Cough Conference
6/6/2023
Algernon Pharmaceuticals Inc. is pleased to announce that it will present its Phase 2a Ifenprodil cough data at the 9 th American Cough Conference (ACC) being held June 9-10, 2023 in Reston, Virginia.
-
Algernon NeuroScience Announces Successful Completion of Highest Planned Single Dose in DMT Phase 1 Trial; Accelerates Plans for Phase 2 Stroke and TBI Studies
6/5/2023
Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) is pleased to advise that its subsidiary Algernon NeuroScience (AGN Neuro), has successfully completed dosing of the third and planned final cohort in its escalating dose Phase 1 clinical study of an intravenous (IV) formulation of AP-188 (“N,N-Dimethyltryptamine” or “DMT”).
-
Algernon Pharmaceuticals Receives Notice of Allowance from the Japanese Patent Office for Repirinast and the Treatment of CKD
5/31/2023
Algernon Pharmaceuticals Inc. is pleased to announce that it has received a Notice of Allowance from the Japanese Patent Office (JPO) for patent application 2021-522114 entitled “Compositions and Methods for Treating Chronic Kidney Disease” for its lead chronic kidney disease (CKD) program drug NP-251.
-
Algernon Pharmaceuticals Announces Closing of Rights Offering
5/5/2023
Algernon Pharmaceuticals Inc. announces that it has closed its previously announced rights offering which expired on April 27, 2023 (the “ Rights Offering ”).
-
Algernon Pharmaceuticals Reminds Shareholders of Previously Announced Rights Offering and Approaching Cut Off Date and Time
4/20/2023
Algernon Pharmaceuticals Inc. is reminding its shareholders of the details of its previously announced rights offering as well as the cut off date and time for the exercise of those rights.
-
Algernon Pharmaceuticals Announces Notice of Allowance for Method of Use U.S. Patent Application
4/17/2023
Algernon Pharmaceuticals Inc. is pleased to announce that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for patent application 17/258,402 entitled “Compositions and Methods for Treating Non-Alcoholic Steatohepatitis” for its lead chronic kidney Disease (CKD) program drug NP-251 (Repirinast).
-
Algernon NeuroScience Announces Successful Dosing of 2nd Cohort in Phase 1 DMT Clinical Study
4/4/2023
Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) is pleased to advise that its subsidiary Algernon NeuroScience (AGN Neuro), has completed dosing of the second cohort in its escalating dose Phase 1 clinical study of an intravenous formulation of AP-188 (“N,N-Dimethyltryptamine” or “DMT”).
-
Algernon Pharmaceuticals Announces Launch of Rights Offering
3/21/2023
Algernon Pharmaceuticals Inc. announces it is undertaking a rights offering to raise gross proceeds of approximately $2,416,747 (the “Rights Offering”).